(Photo: Shutterstock)
It's commonly known that the cost of prescription drugs in the U.S. has been rising well above inflation, 7.5% in some cases. Ironically, the current pandemic-driven inflation rate may technically put an end to that, though sadly it will not stop rising drug prices.
According to the IQVIA Institute, specialty drugs account for 53% and branded drugs account for 30% of the overall drug spend, most of which are still under patent with limited competition. However, generics and biosimilar drugs are available at a substantially lower price for some of these drugs, but surprisingly, evidence shows that these lower cost options are often excluded from our formularies by the very vendor we entrust to manage our costs.
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
